This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2005 Nov 12;331(7525):1144-5.

doi: 10.1136/bmj.331.7525.1144-c.

Orphan drugs and the NHS: fairness in health care entails more than cost effectiveness

PMID: 16282416
PMCID: PMC1283316
DOI: 10.1136/bmj.331.7525.1144-c

Comment

Orphan drugs and the NHS: fairness in health care entails more than cost effectiveness

Mark Sheehan. BMJ. 2005.

. 2005 Nov 12;331(7525):1144-5.

doi: 10.1136/bmj.331.7525.1144-c.

Author

PMID: 16282416
PMCID: PMC1283316
DOI: 10.1136/bmj.331.7525.1144-c

No abstract available

PubMed Disclaimer

Comment on

Orphan drugs and the NHS: should we value rarity?
McCabe C, Claxton K, Tsuchiya A. McCabe C, et al. BMJ. 2005 Oct 29;331(7523):1016-9. doi: 10.1136/bmj.331.7523.1016. BMJ. 2005. PMID: 16254305 Free PMC article. Review.

Similar articles

Orphan drugs and the NHS: should we value rarity?
McCabe C, Claxton K, Tsuchiya A. McCabe C, et al. BMJ. 2005 Oct 29;331(7523):1016-9. doi: 10.1136/bmj.331.7523.1016. BMJ. 2005. PMID: 16254305 Free PMC article. Review.
Orphan drugs and the NHS: consider whom drug regulation is designed to protect.
Marshall T. Marshall T. BMJ. 2005 Nov 12;331(7525):1144. doi: 10.1136/bmj.331.7525.1144-b. BMJ. 2005. PMID: 16282417 Free PMC article. No abstract available.
Societal Preferences for Funding Orphan Drugs in the United Kingdom: An Application of Person Trade-Off and Discrete Choice Experiment Methods.
Bourke SM, Plumpton CO, Hughes DA. Bourke SM, et al. Value Health. 2018 May;21(5):538-546. doi: 10.1016/j.jval.2017.12.026. Value Health. 2018. PMID: 29753350
Drugs for exceptionally rare diseases: do they deserve special status for funding?
Hughes DA, Tunnage B, Yeo ST. Hughes DA, et al. QJM. 2005 Nov;98(11):829-36. doi: 10.1093/qjmed/hci128. Epub 2005 Oct 3. QJM. 2005. PMID: 16203824 Review.
Cost-effectiveness assessment of orphan drugs: a scientific and political conundrum.
Simoens S, Picavet E, Dooms M, Cassiman D, Morel T. Simoens S, et al. Appl Health Econ Health Policy. 2013 Feb;11(1):1-3. doi: 10.1007/s40258-012-0004-y. Appl Health Econ Health Policy. 2013. PMID: 23329382 No abstract available.

See all similar articles

Cited by

Debates over orphan drug pricing: a meta-narrative literature review.
Hanchard MS. Hanchard MS. Orphanet J Rare Dis. 2025 Mar 7;20(1):107. doi: 10.1186/s13023-025-03634-2. Orphanet J Rare Dis. 2025. PMID: 40055799 Free PMC article. Review.
A systematic review of moral reasons on orphan drug reimbursement.
Zimmermann BM, Eichinger J, Baumgartner MR. Zimmermann BM, et al. Orphanet J Rare Dis. 2021 Jun 30;16(1):292. doi: 10.1186/s13023-021-01925-y. Orphanet J Rare Dis. 2021. PMID: 34193232 Free PMC article.
Potential impact of the implementation of multiple-criteria decision analysis (MCDA) on the Polish pricing and reimbursement process of orphan drugs.
Kolasa K, Zwolinski KM, Kalo Z, Hermanowski T. Kolasa K, et al. Orphanet J Rare Dis. 2016 Mar 10;11:23. doi: 10.1186/s13023-016-0388-0. Orphanet J Rare Dis. 2016. PMID: 26965710 Free PMC article.
Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countries.
Zelei T, Molnár MJ, Szegedi M, Kaló Z. Zelei T, et al. Orphanet J Rare Dis. 2016 Jun 4;11(1):72. doi: 10.1186/s13023-016-0455-6. Orphanet J Rare Dis. 2016. PMID: 27259284 Free PMC article.

References

1. McCabe C, Claxton K, Tsuchiya A. Orphan drugs and the NHS: should we value rarity? BMJ 2005;331: 1016-9. (29 October.) - PMC - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information